0.49
price up icon0.08%   0.0004
after-market After Hours: .47 -0.02 -4.08%
loading
Ovid Therapeutics Inc stock is traded at $0.49, with a volume of 164.13K. It is up +0.08% in the last 24 hours and down -14.89% over the past month. Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential in-class mechanism of action.
See More
Previous Close:
$0.4896
Open:
$0.51
24h Volume:
164.13K
Relative Volume:
0.44
Market Cap:
$34.79M
Revenue:
$391.70K
Net Income/Loss:
$-52.34M
P/E Ratio:
-0.6533
EPS:
-0.75
Net Cash Flow:
$-45.92M
1W Performance:
-3.92%
1M Performance:
-14.89%
6M Performance:
-56.25%
1Y Performance:
-83.33%
1-Day Range:
Value
$0.463
$0.51
1-Week Range:
Value
$0.463
$0.58
52-Week Range:
Value
$0.463
$3.45

Ovid Therapeutics Inc Stock (OVID) Company Profile

Name
Name
Ovid Therapeutics Inc
Name
Phone
212-776-4381
Name
Address
441 NINTH AVENUE, 14TH FLOOR, NEW YORK, NY
Name
Employee
25
Name
Twitter
@OvidRx
Name
Next Earnings Date
2024-11-04
Name
Latest SEC Filings
Name
OVID's Discussions on Twitter

Compare OVID with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
OVID
Ovid Therapeutics Inc
0.49 34.79M 391.70K -52.34M -45.92M -0.75
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
488.34 125.40B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
718.16 78.51B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
580.43 35.27B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
238.74 30.91B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beone Medicines Ltd Adr
245.71 26.37B 3.32B -860.46M -1.04B -8.32

Ovid Therapeutics Inc Stock (OVID) Upgrades & Downgrades

Date Action Analyst Rating Change
Jun-18-24 Downgrade Oppenheimer Outperform → Perform
Apr-30-24 Initiated B. Riley Securities Buy
Apr-29-24 Initiated H.C. Wainwright Buy
Apr-05-24 Initiated Wedbush Outperform
Dec-21-23 Initiated BTIG Research Buy
Oct-13-23 Initiated Oppenheimer Outperform
Apr-20-21 Downgrade Cantor Fitzgerald Buy → Neutral
Mar-03-21 Downgrade RBC Capital Mkts Outperform → Sector Perform
Dec-02-20 Downgrade Citigroup Buy → Neutral
Dec-02-20 Downgrade JMP Securities Mkt Outperform → Mkt Perform
Sep-04-19 Initiated RBC Capital Mkts Outperform
Apr-20-18 Initiated Ladenburg Thalmann Buy
View All

Ovid Therapeutics Inc Stock (OVID) Latest News

pulisher
Mar 11, 2025

Ovid Therapeutics earnings beat by $0.04, revenue fell short of estimates - Investing.com UK

Mar 11, 2025
pulisher
Mar 11, 2025

Ovid Therapeutics stock plunges to 52-week low of $0.46 - Investing.com India

Mar 11, 2025
pulisher
Mar 11, 2025

Ovid Therapeutics (OVID) Reports Q4 Loss, Lags Revenue Estimates - Yahoo Finance

Mar 11, 2025
pulisher
Mar 11, 2025

Ovid Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView

Mar 11, 2025
pulisher
Mar 11, 2025

Ovid Therapeutics Reports Business Updates and Fourth Quarter and Full Year 2024 Financial Results - The Manila Times

Mar 11, 2025
pulisher
Mar 11, 2025

We're A Little Worried About Ovid Therapeutics' (NASDAQ:OVID) Cash Burn Rate - Yahoo Finance

Mar 11, 2025
pulisher
Mar 07, 2025

Ovid Therapeutics (OVID) Expected to Announce Earnings on Friday - Defense World

Mar 07, 2025
pulisher
Mar 06, 2025

Trump's FDA chief pick Makary to face overhauling agency, keeping Kennedy happy -March 06, 2025 at 06:00 am EST - Marketscreener.com

Mar 06, 2025
pulisher
Mar 06, 2025

Ovid Therapeutics Inc. (NASDAQ:OVID) Receives $4.03 Consensus Target Price from Brokerages - Defense World

Mar 06, 2025
pulisher
Mar 05, 2025

Ovid Therapeutics appoints new board member and updates compensation policy - Investing.com India

Mar 05, 2025
pulisher
Mar 05, 2025

Ovid Therapeutics appoints new board member and updates compensation policy By Investing.com - Investing.com South Africa

Mar 05, 2025
pulisher
Mar 05, 2025

Ovid Therapeutics Expands Board with New Appointment - TipRanks

Mar 05, 2025
pulisher
Mar 04, 2025

Ovid Therapeutics Inc expected to post a loss of 17 cents a shareEarnings Preview - TradingView

Mar 04, 2025
pulisher
Mar 03, 2025

Ovid Therapeutics Appoints Dr. Stelios Papadopoulos To Board - citybiz

Mar 03, 2025
pulisher
Mar 03, 2025

Ovid Therapeutics Appoints Pioneering Industry Leader Dr. Stelios Papadopoulos to Board of Directors - GlobeNewswire

Mar 03, 2025
pulisher
Mar 01, 2025

Ovid therapeutics CBFO sells $2,185 in stock - Investing.com India

Mar 01, 2025
pulisher
Mar 01, 2025

Ovid therapeutics CBFO sells $2,185 in stock By Investing.com - Investing.com Australia

Mar 01, 2025
pulisher
Feb 28, 2025

Ovid therapeutics president and COO sells $2,956 in stock By Investing.com - Investing.com Canada

Feb 28, 2025
pulisher
Feb 28, 2025

Ovid therapeutics president and COO sells $2,956 in stock - Investing.com India

Feb 28, 2025
pulisher
Feb 27, 2025

Ovid Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference - GlobeNewswire

Feb 27, 2025
pulisher
Feb 27, 2025

Want Insights on Brain Condition Treatments? Ovid Therapeutics Set for Major Healthcare Conference - StockTitan

Feb 27, 2025
pulisher
Feb 25, 2025

Ovid Therapeutics stock hits 52-week low at $0.55 - Investing.com India

Feb 25, 2025
pulisher
Feb 25, 2025

Ovid Therapeutics stock hits 52-week low at $0.55 By Investing.com - Investing.com UK

Feb 25, 2025
pulisher
Feb 20, 2025

Epilepsy Market Assessment in the 7MM by 2034 — A Detailed Analysis of Growth Prospects Across Different Types | DelveInsight - GlobeNewswire Inc.

Feb 20, 2025
pulisher
Feb 19, 2025

Analyzing Madrigal Pharmaceuticals (NASDAQ:MDGL) & Ovid Therapeutics (NASDAQ:OVID) - Defense World

Feb 19, 2025
pulisher
Feb 18, 2025

Dup15q Syndrome Market Expected to rise, 2032 | Ovid - openPR

Feb 18, 2025
pulisher
Feb 15, 2025

SG Americas Securities LLC Purchases 17,172 Shares of Ovid Therapeutics Inc. (NASDAQ:OVID) - Defense World

Feb 15, 2025
pulisher
Feb 14, 2025

Ovid Therapeutics faces Nasdaq delisting over share price - MSN

Feb 14, 2025
pulisher
Feb 13, 2025

Ovid Therapeutics faces Nasdaq delisting over share price By Investing.com - Investing.com South Africa

Feb 13, 2025
pulisher
Feb 13, 2025

Ovid Therapeutics IncReceives Nasdaq Notice For Minimum Bid Price Non-Compliance - Marketscreener.com

Feb 13, 2025
pulisher
Feb 12, 2025

Ovid stock plunges to 52-week low, touches $0.59 amid downturn - MSN

Feb 12, 2025
pulisher
Feb 11, 2025

Ovid therapeutics president and COO acquires $4,971 in stock - MSN

Feb 11, 2025
pulisher
Feb 10, 2025

Dup15q Syndrome Drugs Market Size Report 2032 | Ovid - openPR

Feb 10, 2025
pulisher
Feb 06, 2025

Ovid Therapeutics to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference - GlobeNewswire

Feb 06, 2025
pulisher
Feb 05, 2025

Epilepsy Market Expected to rise, 2034 | Xenon Pharmaceuticals, Aquestive Therapeutics, Atnahs Pharma (Pharmanovia), Takeda, Ovid Therapeutics, SK Biopharmaceuticals (SK Life Science), Eisai, Biohaven - Barchart

Feb 05, 2025
pulisher
Feb 05, 2025

Healthcare Spotlight: Ovid Therapeutics Takes Center Stage at Major Oppenheimer Conference - StockTitan

Feb 05, 2025
pulisher
Feb 03, 2025

Ovid Therapeutics (NASDAQ:OVID) Upgraded by Oppenheimer to Outperform Rating - MarketBeat

Feb 03, 2025
pulisher
Feb 01, 2025

Oppenheimer raises Ovid stock rating, sets $4 price target - MSN

Feb 01, 2025
pulisher
Feb 01, 2025

Ovid Therapeutics stock hits 52-week low at $0.68 amid downturn - MSN

Feb 01, 2025
pulisher
Jan 31, 2025

Ovid upgraded to outperform by Oppenheimer, OV329 cited - MSN

Jan 31, 2025
pulisher
Jan 30, 2025

Ovid Therapeutics upgraded at Oppenheimer as OV329’s promise ‘quite real’ - Yahoo Finance

Jan 30, 2025

Ovid Therapeutics Inc Stock (OVID) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$70.49
price down icon 2.14%
$18.50
price up icon 2.83%
$304.42
price down icon 4.23%
$32.46
price down icon 0.89%
$98.39
price down icon 6.61%
biotechnology ONC
$245.71
price up icon 1.26%
Cap:     |  Volume (24h):